Smallpox vaccine–induced antibodies are necessary and sufficient for protection against monkeypox vi
Author: ["Yvette Edghill-Smith","Hana Golding","Jody Manischewitz","Lisa R King","Dorothy Scott","Mike Bray","Aysegul Nalca","Jay W Hooper","Chris A Whitehouse","Joern E Schmitz","Keith A Reimann","Genoveffa Franchini"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Vaccination with live vaccinia virus affords long-lasting protection against variola virus, the agent of smallpox. Its mode of protection in humans, however, has not been clearly defined. Here we report that vaccinia-specific B-cell responses are essential for protection of macaques from monkeypox virus, a variola virus ortholog. Antibody-mediated depletion of B cells, but not CD4+ or CD8+ T cells, abrogated vaccine-induced protection from a lethal intravenous challenge with monkeypox virus. In addition, passive transfer of human vaccinia-neutralizing antibodies protected nonimmunized macaques from severe disease. Thus, vaccines able to induce long-lasting protective antibody responses may constitute realistic alternatives to the currently available smallpox vaccine (Dryvax).
Cite this article
Edghill-Smith, Y., Golding, H., Manischewitz, J. et al. Smallpox vaccine–induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11, 740–747 (2005). https://doi.org/10.1038/nm1261
